Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
60 results about "Bone marrow transplants" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Combination therapy for treating, preventing or managing proliferative disorders and cancers
InactiveUS20040067953A1Improve efficiencyImprove toleranceBiocideHeavy metal active ingredientsCancer preventionBiologically-Based Therapy
The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies.
Owner:SIGNAL PHARMA LLC
Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state
Pluri-differentiated human mesenchymal progenitor cells (MPCs) are isolated. A method isolates and purifies human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.
Owner:SOUTH FLORIDA UNIVESITY OF
Thienotriazolodiazepine compound and medicinal use thereof
ActiveUS20100041643A1Induce antigen specific immunological toleranceAvoid signalingBiocideSenses disorderImmunologic disordersAutoimmune disease
[Solving means] A thienotriazolodiazepine compound of the following formula (I)a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound.[Effect]Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.
Owner:MITSUBISHI TANABE PHARMA CORP
Methods for extending the replicative lifespan of cells
InactiveUS20070160586A1Increase capacityProlong replicative lifespanBiocideCompound screeningActive agentOrganogenesis
The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured cells can be used for a variety of applications including cell-based therapies such as bone marrow transplants, gene therapies, tissue engineering, and in vitro organogenesis.
Owner:CHILDRENS MEDICAL CENT CORP
Combination therapy for treating or managing acute myelocytic leukemia
InactiveUS20070149571A1Improve efficiencyImprove toleranceHeavy metal active ingredientsBiocideCancer preventionRadical radiotherapy
Owner:SIGNAL PHARMA LLC
Mobilization of hematopoietic cells
ActiveUS20050142103A1Effective level of cellEffective levelingAntibacterial agentsOrganic active ingredientsDiseaseHematopoietic cell
Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve inhibition of both Rac1 and Rac2 GTPases to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. The subject's blood can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient and may in the future be utilized to repair a variety of non-hematopoietic tissues. Therefore, hematopoietic stem cells mobilized into a subject's peripheral blood by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. They can also be used for increasing white blood cell survival and for chemotherapy.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI
Test strip for specifically measuring IgM, IgG and IgA blood group antibodies
The invention belongs to the field of biological medicines and discloses an immunochromatography test paper technology, which is used for specifically measuring the negative, positive and titer of IgM, IgG and IgA blood group antibodies in blood or body fluid or tissue fluid or secretion of people. The technology comprises the following steps: (1) preparing a sample filter membrane and a sample pad; (2) preparing a tracer and a tracing pad; (3) preparing a fiber membrane detection area and a quality control area; (4) labeling a test strip; (5) assembling the test strip; (6) injecting a sample and detecting; and (7) reading a result. The test strip can be used for measuring IgM anti-A and anti-B antibody titer, monitoring implantation of bone marrow transplantation and measuring the titer of immune IgG anti-A and anti-B antibodies of individuals, particularly prenatal pregnant women and newborns, the reverse typing of blood groups can be accurately judged by specifically measuring the IgM anti-A and anti-B antibodies, and the reverse typing of the blood group of an individual can be judged through saliva without blood sampling by specifically measuring IgA anti-A and anti-B antibodies in secretion.
Owner:邵超鹏
Therapeutic methods employing nitric oxide precursors
Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.
Owner:VANDERBILT UNIV
Acetylcysteine gargle for treating dental ulcers, and preparation method thereof
InactiveCN103027891ARich varietyPrevent ulcersOrganic active ingredientsDigestive systemOral ulcersEfficacy
The invention discloses an acetylcysteine gargle for treating dental ulcers, and a preparation method thereof. The preparation method comprises the following steps: cooling a small amount of purified water by mass percent; adding the acetylcysteine and then stirring and mixing; under a stirring action, regulating the pH value until the acetylcysteine is dissolved; adding a solution stabilizer, a corrigent and a corrosion remover and mixing; adding poloxamer and then stirring till dissolving; statically placing an obtained mixture; filtering the mixture; and adding the water to a filtrate, thereby obtaining the acetylcysteine gargle. The acetylcysteine gargle prepared by using the method has the functions of quickly relieving pain and preventing / treating the ulcers, and especially has the medicinal efficacy of inhibiting the continuous ulcer expansion and promoting the ulcer wound healing for patients accepting radiotherapy, chemotherapy and bone marrow transplantation. The method provided by the invention has the advantages of simple preparation process and easiness in industrial scale production realization. The acetylcysteine gargle provided by the invention has the advantages of high stability, single and clear active ingredients and good quality controllability, thereby enriching the drug category for adjuvant therapy of clinical cancer. Therefore, a good selection for the nursing service of the patients accepting the radiotherapy is provided.
Owner:TIANJIN KUNJIAN BIOLOGICAL PHARMA
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.
Owner:IMPETIS BIOSCI LTD
Chinese patent medicine for treating aplastic anemia
ActiveCN102274417AThe composition is lessCollocation scienceBlood disorderExtracellular fluid disorderClinical efficacyCurative effect
The invention discloses a Chinese patent medicament for treating aplastic anemia. The Chinese patent medicament comprises the following Chinese herbal medicines: prepared rehmannia root, figwort root, dwarf lilyturf tuber, oriental waterplantain rhizome, mulberry, India madder root, gardenia, tree paeony bark, lalang grass rhizome and the like. The Chinese patent medicament contains fewer ingredients according to a formula, is mixed scientifically, does not have toxic or side effect, and has an obvious treatment effect on acute and chronic aplastic anemia. By the treatment with the Chinese patent medicament, the effective rate of the aplastic anemia is over 90 percent, and the cure rate is over 80 percent. The Chinese patent medicament has a good clinical treatment effect on aplastic anemia and has the high safety of clinical administration, and bone marrow transplantation is prevented, so the treatment cost is low.
Owner:魏兴禹
Method for analyzing mixed sample DNA
PendingCN110157786ASuitable for forensic testingProtection securityMicrobiological testing/measurementOrgan transplantationBone marrow transplantations
The invention discloses a method for analyzing mixed sample DNA. The mixed sample DNA is analyzed with a method combining INDEL with Microhaplotypes; in other words, father source or mother source DNAof an individual is sorted through differential amplification of the INDEL, and then individual distinguishing is conducted through the Microhaplotypes on DNA molecules; the method is named a DIP-Microhaplotypes method. The method has the advantages that analysis of a mixed DNA sample of two samples and detection of mixed stain sensitivity mainly depend on the INDEL, following detection of SNP isrelated to a detection means, and mixed stains can be successfully analyzed and used for excluding or confirming the individual; an INDEL-SNP primer has species specificity and is suitable for forensic medicine detection; the method is possibly used for monitoring transplant ingredients in peripheral blood after a bone marrow transplantation operation or other organ transplantation operations; the method is possibly used for all cases where individuals need to be distinguished when the mixed sample is involved.
Owner:SHANXI MEDICAL UNIV
Amine compound and use thereof for medical purposes
ActiveUS20150087620A1Superior peripheral blood lymphocyte decreasing actionEliminate side effectsBiocideNervous disorderAutoimmune conditionGraft versus host disease induction
The present invention provides a compound represented by the following formula (I):wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.
Owner:MITSUBISHI TANABE PHARMA CORP
Relationship of ABC transport proteins with hematopoietic stem cells and methods of use thereof
The present invention includes methods of performing ex vivo expansion of gene-modified hematopoietic stem cells which are useful for many applications involving bone marrow transplantation and ex vivo gene therapy. The present invention further includes the gene-modified hematopoietic stem cells that are used and produced by such methods. Such gene-modified hematopoietic stem cells can also contain a second heterologous gene. In addition, the present invention also includes methods of engrafting the gene-modified hematopoietic stem cells of the present invention into animals, including for ex vivo gene therapy and for reconstitution of hematopoietic cells in ablated mammals. The present invention also provides a method of isolating stem cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Human mesenchymal progenitor cell
InactiveUS20050142119A1BiocideMicrobiological testing/measurementProgenitorBone marrow transplantations
There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.
Owner:SOUTH FLORIDA UNIVESITY OF
Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
ActiveUS7138144B2Reduced doses of bone marrow cellsPreventing graft-versus-host diseaseBiocideGenetic material ingredientsImmune toleranceLymph flow
Owner:CELLECT BIOTECH
Recombinant human platelet auxin/dry cell factor fusion protein and preparation thereof
The invention is the gene engineering preparation polypeptide remedy technology field of biology technology. The aid is to build a double function fusion albumen gene of rhTPO / SCF, express and prepare with more biology activityú¼less side-effect rhTPO / SCF in insect cell. The gene of rhTPO / SCF includes 1-157 amino acids coding sequence with TPO, 16 amino acids continual peptide coding sequence, 1-145 amino acids coding sequence of SCF and codoní»s DNA fragments. By taking the rhTPO / SCF into TF1 cells experiment, which preparation from the infect recombination virus growing in adherence S19 cell, it mensurates that the specific activity is 2.0 í10 to the power 5 units / mg; by Mo7e cells experiment, the specific activity is 8.3í10 to the power 5 units / mg. It can be used to cure low blood platelet cause by radiotherapy, chemotherapy, bone marrow transplantationíú
Owner:NANJING UNIV
CXCR4 Receptor Compounds
InactiveUS20130005944A1Promote wound healingReduce scarsPeptide/protein ingredientsDepsipeptidesUveitisFibrosis
The invention relates generally to compounds which are allosteric modulators {e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CXCR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow transplantation, chemosensitization, cancer, metastatic disease (e.g., cancer), auto-immune disease (e.g., rheumatoid arthritis), fibrosis disease (e.g., pulmonary), AIDS infection, cardiovascular disease, uveitis, inflammatory diseases, celiac disease HIV infection and stem cell-based regenerative medicine.
Owner:ACER THERAPEUTICS INC
Hematopoietic stem cell growth factor (SCGF)
InactiveUS6541217B2Readily aspiratedShort timeBacteriaPeptide/protein ingredientsHematopoietic stem cell transplantationGene transfer
The present invention provides a novel polypeptide possessing growth activities on hematopoietic stem cells, a gene encoding the polypeptide and an antibody reacting specifically with the polypeptide, as well as a method for isolating the above gene and a vector for use in the method. According to the present invention, it is possible to elucidate the pathogenesis of various hematopoietic diseases due to abnormalities in hematopoietic stem cells and of bone marrow inhibition, and to diagnose and treat such diseases. According to the present invention, it is also possible to amplify hematopoietic stem cells in vitro for bone marrow transplantation necessary for the treatment of such diseases or improve efficiency of a gene transfer into hematopoietic stem cells for utilizing the gene therapy. The vector and the method of gene isolation developed to isolate the SCGF gene of the invention are applicable to search for other novel genes and able to contribute to the technological progress in genetic engineering.
Owner:HIRAOKA ATSUNOBU +1
Interferential RNA retrovirus and its preparation and use
InactiveCN1654637AHigh technical contentTo achieve the purpose of curing diseasesViruses/bacteriophagesFermentationDiseaseInfected cell
The interference RNA retrovirus is prepared through loading interference RNA to the pathogenetic gene of leukaemia or AIDS. The interference RNA retrovirus is used in infecting bone marrow cell or stem cell of target gene provider and the infected cell is transfused back to the body of the target gene provider. The reconstructed leukocyte has no pathogenetic gene, so that leukaemia or AIDS is cured. The present invention cures diseases through combining modern biological technology and bone marrow transplanting operation to deactivate pathogenetic gene. Owing to that the marrow for transplanting is from the patient, the present invention has no rejection.
Owner:田文志
Method of Producing Recombinant TAT-HOXB4H Protein for Use as a Stimulant of Hematopoiesis In Vivo
ActiveUS20090227496A1High yieldImprove stabilityPeptide/protein ingredientsImmunological disordersCirculating Stem CellHematopoietic cell
The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
Owner:HEXUN BIOSCIENCES CO LTD
Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
InactiveUS20080131498A1Overcomes insolubility problemEliminate side effectsBiocideTetrapeptide ingredientsSide effectOral medication
Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and / or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration or parenteral administration of free drug. The formulations are useful as part of stem cell and / or bone marrow transplant conditioning regimens. A method of treatment of a mammal by use of such formulations.
Owner:BUSULIPO
Recombinant human dyad stem cell factor and preparing thereof
InactiveCN1435426AEasy to separate and purifyImprove secretion efficiencySugar derivativesFermentationFactor iiLinker peptide
A recombinant human diad stem cell factor (rhdSCF) used for radiotherapy, chemicotherapy and recreating and restoring the hematognesis and immune function after bone marrow transplantation is disclosed. It sequentially contains amino acid codons No1-165 of human SCF, 12 amino acid linker peptides, codons No1-145 of human SCF and DNA fragment of termination codon. Its advantage is high specific activity.
Owner:NANJING UNIV
Separation method for hepatic inherent and infiltrating macrophages
PendingCN110669731AAccurate and efficient separationCell dissociation methodsSkeletal/connective tissue cellsHepatic macrophageSurface marker
The invention provides a separation method for hepatic inherent and infiltrating macrophages. The separation method comprises the following steps of (1) establishing and identifying mouse allogeneicbone marrow transplantation model, wherein a surface marker of a mononuclear macrophage of a recipient mouse is CD45.2, and a surface marker of a mononuclear macrophage of a donor mouse is CD45.1; (2)observing and irradiating the influence on hepatic parenchymal cells and inherent macrophages with an IHC method and a flow cytometry; and (3) irradiating a mononuclear cell of a mouse liver in a transplantation group with primary isolation, and sorting the hepatic inherent and infiltrating macrophages with the flow cytometry according to the surface marker of the mononuclear macrophage of the donor mouse, and describing the quantities, distribution and phenotypes of the hepatic inherent and infiltrating macrophages. In the separation method provided by the invention, by removing the CD45.2 recipient mouse bone marrow derived macrophages by irradiation and supplementing and replacing bone marrow cells of the recipient mouse with CD45.1 donor mouse bone marrows, the bone marrow derived infiltrating macrophages and the bone marrow derived inherent macrophages have different molecular phenotypes and achieves the effect of accurately and efficiently separating different hepatic macrophages.
Owner:NANTONG UNIVERSITY
Application of vitamin D3 in preparing medicine for treating multiple myeloma
InactiveCN102648917AConvenient treatmentTreatment hasDipeptide ingredientsBoron compound active ingredientsSignalling pathwaysTherapeutic effect
The invention discloses medicine for treating multiple myeloma, and particularly relates to application of vitamin D3 and derivatives thereof in preparing a pharmaceutical composition for treating multiple myeloma. The medicine has the principle of treatment that vitamin D3 is mainly acted on a tumour cell Hedgehog (Hh) signaling pathway, and is used for inhibiting accumulation of Smoothened (Smo) protein in the pathway, so that the aim of inhibiting tumor growth is achieved. Compared with bortezomib, the vitamin D3 almost has no toxicity, and in mouse test, no accidental death caused by drug toxicity occurred. The clinical trials indicate that the medicine has a therapeutical effect on patient with types of multiple myeloma, and particularly has a better therapeutical effect for patients after the transplantation of bone marrow. 30 clinical trial patient treatment indicates that the total effective rate achieves 96.7 percent. In addition, the medicine is combined with the bortezomib, so that a synergistic effect is realized.
Owner:CHINA PHARM UNIV
Human dry cell factor macrophage clong irritant factor bifunction protein and its preparation
A dual-function protein human stem cell factor-macrophage colony stimulating factor (hSCF / M-CSF) and a process for preparing its recombinant one (rhSCF / M-CSF) by efficient secretion expression in insect are disclosed. It can be used for rebuilding and restoring the hematopoietic and immune functions of a patient after radiotherapy, chemicotherapy and bone marrow transplantation.
Owner:NANJING UNIV
Methods of treatment of hematopoietic disorders
InactiveUS7347999B2Advantageously facilitatedBiocidePeptide/protein ingredientsGraft ToleranceNon malignant
A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and / or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation / implantation thereof. The composition and methods of the invention enable restoring and / or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and / or their products, genetic conditions resulting in abnormal stem cells and / or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and / or MBM.
Owner:SLAVIN SHIMON
Method for transplanting lymphohematopoietic cells into mammal
The present invention provides a method for transplanting lymphohematopoietic cells into a mammal, which comprises the step of injecting cells into a bone marrow cavity, and wherein the cells have an exogenous gene encoding a receptor that induces cell proliferation in response to ligand binding. By combining intra-bone marrow transplantation (iBMT) and selective amplifier gene (SAG), marrow conditioning before the injection of the cells can be omitted. The present invention further provides a bone marrow transplant and a kit for transplanting lymphohematopoietic cells into mammals. Furthermore, the invention provides an SAG particularly suitable for such transplantation.
Owner:DNAVEC RES
Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient
ActiveUS10792309B2Reducing graft-versus-host disease and immune diseaseSuppression of rejectionMammal material medical ingredientsSkeletal/connective tissue cellsMesenchymal stem cellImmunomodulations
The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.
Owner:LUCAS BIO CO LTD
Medicament for curing chronic aplastic anemia and preparation method thereof
InactiveCN101518606AComply with the provisions of the Food Sanitation LawSafe to takeAnthropod material medical ingredientsBlood disorderMedicinal herbsRhizome
The invention provides a medicament for curing chronic aplastic anemia and a preparation method thereof. The medicament is prepared by the following raw materials: purple beautyberry, notoginseng, ginseng, wolfberry fruit, donkey-hide gelatin beads, Chinese caterpillar fungus, prepared rehmannia root, white atractylodes rhizome, dogwood fruit, rhizoma discoreae, Chinese angelica, honey, and the like, and according to the characteristics of different tastes, channel tropism, function and principle indications of all the Chinese medicinal herbs, the Chinese medicinal herbs are respectively screened, processed according to the weight (portion) proportion, dried, crushed, melted, evenly mixed and milled into honeyed pills, and the sterilization and the packaging by vacuum film pressing are performed to the honeyed pills. The medicament has good effect for curing the chronic aplastic anemia, is convenient to safely and efficiently take by patients who do not need to suffer from blood transfusion and bone morrow transplantation and take hormone medicine, has low treatment cost, and the like.
Owner:肖学成
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com